Danaher (NYSE:DHR) Price Target Raised to $315.00

Danaher (NYSE:DHR) had its target price lifted by research analysts at TD Cowen from $310.00 to $315.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the conglomerate’s stock. TD Cowen’s target price suggests a potential upside of 27.08% from the company’s previous close.

DHR has been the topic of several other research reports. KeyCorp upped their price objective on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday. Robert W. Baird cut their price objective on Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a report on Wednesday. Bank of America boosted their target price on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Barclays cut their price target on Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research note on Wednesday. Finally, The Goldman Sachs Group boosted their price target on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $287.28.

Danaher Price Performance

DHR opened at $247.88 on Wednesday. Danaher has a 12-month low of $182.09 and a 12-month high of $281.70. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $183.60 billion, a P/E ratio of 42.03, a PEG ratio of 4.49 and a beta of 0.83. The stock has a fifty day moving average of $270.43 and a 200-day moving average of $260.43.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same period last year, the company posted $2.02 EPS. Equities analysts forecast that Danaher will post 7.59 EPS for the current fiscal year.

Insider Buying and Selling at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Linda Filler sold 3,928 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $279.50, for a total value of $1,097,876.00. Following the completion of the sale, the director now owns 41,149 shares of the company’s stock, valued at $11,501,145.50. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 30,059 shares of company stock valued at $8,400,897 in the last 90 days. 11.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Danaher

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in Danaher by 7.4% in the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after acquiring an additional 4,163,657 shares during the period. Swedbank AB acquired a new position in shares of Danaher in the 1st quarter worth approximately $676,545,000. TD Asset Management Inc lifted its position in shares of Danaher by 99.0% during the 2nd quarter. TD Asset Management Inc now owns 1,358,706 shares of the conglomerate’s stock worth $339,473,000 after buying an additional 675,952 shares during the period. Massachusetts Financial Services Co. MA boosted its stake in Danaher by 22.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock valued at $761,475,000 after buying an additional 563,546 shares in the last quarter. Finally, International Assets Investment Management LLC grew its position in Danaher by 40,196.5% in the third quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock valued at $119,539,000 after acquiring an additional 428,897 shares during the period. 79.05% of the stock is owned by institutional investors.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.